Silo Pharma issues warrant for up to 300,000 shares in unregistered sale under asset purchase deal
SILO•Silo Pharma entered an asset purchase agreement with Norsight Consulting and issued an unregistered warrant for up to 300,000 shares, exercisable at $1.51 per share from April 1, 2027, through September 30, 2031.
1. Warrant terms
The warrant was issued under an asset purchase agreement with Norsight Consulting. Exercise is limited if it would raise Norsight’s ownership above 4.99%, a cap that can be adjusted up to 9.99% with notice. Shares received are subject to a lock-up of up to 12 months, with exceptions for a change in control or company consent. The sale relied on the Securities Act Section 4(a)(2) exemption.
